PMAH PlasmaTech Inc (CE)

Director Compensation

The following table sets forth director compensation as of December 31, 2007:

-4-

(1) Mr. Brough has served as a Director since July 14, 2004, and has received no compensation as an executive officer or Director from the year ended December 31, 2007 through the date of filing of this information statement on Schedule 14C.

(2) Mr. McLane has served as a Director since September 5, 2007, and has received no compensation as a Director from the year ended December 31, 2007 through the date of filing of this information statement on Schedule 14C.

Directors of our company who are also employees do not receive cash compensation for their services as directors or members of the committees of the Board of Directors.  All directors may be reimbursed for their reasonable expenses incurred in connection with attending meetings of the Board of Directors or management committees.

CHANGE IN CONTROL

To the knowledge of management, there are no present arrangements or pledges of securities of PlasmaTech which may result in a change in control of PlasmaTech.

NOTICE TO STOCKHOLDERS OF ACTION APPROVED BY CONSENTING STOCKHOLDER

The following action was taken based upon the unanimous recommendation of PlasmaTech’s Board of Directors (the “Board”) and the written consent of the consenting stockholder:

ACTION 1

AMENDMENT TO THE ARTICLES OF INCORPORATION

TO INCREASE THE AUTHORIZED COMMON STOCK AND PREFERRED STOCK

The Board and the consenting stockholder unanimously adopted and approved an amendment to PlasmaTech’s Articles of Incorporation to increase the number of shares of authorized common stock, par value $0.001 per share, from 75,000,000 to 200,000,000. Such amendment is referred to as the “Authorized Shares Amendment.”

Currently, PlasmaTech has 75,000,000 shares of common stock authorized, of which 70,920,000 are issued and outstanding as of the record date, and no shares of preferred stock authorized.

The increase in the number of shares of common stock authorized provides the Company with increased financial flexibility in meeting future capital requirements. The Board believes that it is advisable and in the best interests of PlasmaTech to have available additional authorized but unissued shares of common stock in an amount adequate to provide for PlasmaTech’s future needs. The unissued shares of common stock will be available for issuance from time to time as may be deemed advisable or required for various purposes, including the issuance of shares in connection with financing or acquisition transactions. The Board would be able to authorize the issuance of shares common stock for these transactions without the necessity, and related costs and delays, of either calling a special meeting of the stockholders or of waiting for the regularly scheduled annual meeting of stockholders in order to increase the authorized capital. If, in a particular transaction, stockholder approval were required by law or any stock exchanges, quotation services or markets or were otherwise deemed advisable by the Board, then the matter would be referred to the stockholders for their approval notwithstanding that PlasmaTech may have the requisite number of voting shares to consummate the transaction.

PlasmaTech has no current plans, proposals or arrangements to issue any shares of its common stock in connection with any transaction.

ACTION 2

AMENDMENT TO THE ARTICLES OF INCORPORATION

TO ELIMINATE PREEMPTIVE RIGHTS OF HOLDERS OF COMMON STOCK

The Board and the consenting stockholder unanimously adopted and approved an amendment to PlasmaTech’s Articles of Incorporation to amend PlasmaTech's Articles of Incorporation to eliminate preemptive rights provided to shareholders. A preemptive right is the right of current shareholders to maintain their fractional or proportional ownership of a company by buying a proportional number of shares of any future issuance of common stock. Preemptive rights give stockholders the right to preempt any issue of stock to any other person

-5-

by purchasing the stock on the same terms and conditions as offered to any non-stockholder. These rights can provide anti-takeover protection to minority shareholders in the event that a company offers to issue additional shares of its common stock to a potential suitor. In such instance, the existing stockholders would have the ability to purchase their pro rata amount, limiting the amount of shares the potential suitor could acquire. Management believes that such rights may delay or prevent future material transactions, including but not limited to materials acquisitions or financing. Additionally, in the event of such transaction, the cost of complying with such shareholder rights would be material, as PlasmaTech would be required to provide notice to all of its stockholders. As PlasmaTech is a public company, such notice would be burdensome and costly. The Board consented to the amendment to PlasmaTech’s Articles of Incorporation to eliminate preemptive rights because of the reasons provided above. The elimination of preemptive rights is a not a corporate action which gives rise to dissenters' rights under the Nevada General Corporation Law.

ADDITIONAL AND AVAILABLE INFORMATION

PlasmaTech is subject to the informational filing requirements of the Exchange Act and, in accordance therewith, is required to file periodic reports, proxy statements and other information with the SEC relating to its business, financial condition and other matters. Such reports, proxy statements and other information can be inspected and copied at the public reference facility maintained by the Securities and Exchange Commission (“SEC”) at 100 F Street, N.E., Washington, D.C. 20549. Information regarding the public reference facilities may be obtained from the SEC by telephoning 1-800-SEC-0330. Our filings are also available to the public on the SEC’s website (www.sec.gov). Copies of such materials may also be obtained by mail from the Public Reference Section of the SEC at 100 F Street N.E., Washington, D.C. 20549 at prescribed rates.